title: Treatment of malignant midgut carcinoid with a highly purified human leukocyte alpha-interferon.
abstract: Fourteen patients with liver metastases due to midgut carcinoid tumours were treated with a highly purified human leukocyte alpha-interferon (Interferon Alfanative) at a dose of 2-6 x 10(6) IU subcutaneously 5 days a week. In all patients, the primary tumour was removed before alpha-interferon was given. We found that after one year of treatment with alpha-interferon, 4 patients (= 29%) showed objective response (= reduction by more than 50% of urinary excretion of 5-HIAA and/or by more than 50% of tumour area as determined by computed tomography). Four patients (= 29%) showed stable disease. After 2 years of treatment with alpha-interferon, 4 patients (= 29%) showed objective response. During the second year of treatment, 3 patients died due to tumour progression and in 4 patients the treatment was stopped due to adverse effects. Specific adverse effects to alpha-interferon were reported by 11 of the patients (= 79%). We conclude that the one year objective response to alpha-interferon in 14 patients with liver metastases due to midgut carcinoids is 29% and that the frequency of side effects is high.
authors.affiliation: Department of Surgery, Lund University, Sweden.
authors.forename: B
authors.initials: B
authors.lastname: Ahren
authors.forename: K
authors.initials: K
authors.lastname: Engman
authors.forename: A
authors.initials: A
authors.lastname: Lindblom
mesh_terms: D000368:Aged; D000906:Antibodies / Q000032:analysis; D002276:Carcinoid Tumor / Q000628:therapy*; D005260:Female; D006801:Humans; D007078:Ileal Neoplasms / Q000628:therapy*; D016898:Interferon-alpha / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged
chemical_list: D000906:Antibodies; D016898:Interferon-alpha